Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

SoliMix – Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes:

Suliqua® (insulin glargine 100 units/mL and lixisenatide) as a favourable alternative to premixed insulin

If you choose to receive emails from Sanofi, they will also use your personal data to send you information by email about goods and services which they feel may be of interest to you on the basis that it is necessary for their legitimate interests (to develop our products/services and grow our business). You may unsubscribe from receiving these emails at any time by following instructions which will be provided in each email. For more details specifically about how Sanofi use your data to send you these emails, please see their separate Staying in Touch Privacy Notice

Prescribing information for Suliqua® (insulin glargine 100 units/mL and lixisenatide) can be found here
This promotional webinar has been initiated and fully funded by Sanofi. The content has been reviewed and approved by the sponsoring company and speakers prior to broadcast. Editorial support for this webinar has been provided by OmniaMed Communications.
© 2021 Sanofi.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Sanofi Tel: 0800 090 2314.Alternatively, send via email to UK-drugsafety@sanofi.com

MAT-GB-2103798 (v1.0) | Date of preparation: September 2021

You are leaving this site.

You are now leaving https://live.diabetesonthenet.com/solimix-advancing-therapy-in-suboptimally-controlled-basal-insulin-treated-type-2-diabetes-suliqua-as-a-favourable-alternative-to-premixed-insulin/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Sanofi.
Sanofi accepts no responsibility for the content or services of the linked site.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.